The U.S. Court of Appeals for the Federal Circuit today denied rehearing and rehearing en banc to Biogen International, which had petitioned the court following a November decision affirming a district court ruling that Biogen’s patent for a method of treating multiple sclerosis (MS) was invalid for lack of written description. Three judges split from the majority, with Judges Lourie, Moore and Newman dissenting on the denial of en banc rehearing. Judge O’Malley had dissented from the November panel decision, but she retired on March 11, 2022, and only participated in the decision on panel rehearing.
Recent Posts
- Revised Fair Use Ruling Finds No Transformative Use in Developing AI Search Tool
- Patently Strategic Podcast: Dealing with Rejection
- IPWatchdog Unleashed: Patents and the Future of the USPTO in Trump’s Second Term
- No Infringement Intended – The World Wrestling Federation’s Biggest Fight: A Look at Trademark Law and Global Brand Recognition
- Other Barks & Bites for Friday, February 7: CAFC Rejects Untimely Expert Testimony and Reassigns Case; CJEU Clarifies Online Marketplace Responsibilities Under GDPR; and IPWATCHPUPPIES ARE ON THE WAY!